Skip to main content
OpenTrials
Completed

NCT Number: NCT01480479

Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma

This 2-arm, randomized, phase III study will investigate the efficacy and safety of the addition of rindopepimut (an experimental cancer vaccine that may act to promote anti-cancer effects in patients who have tumors that express the EGFRvIII protein) to the current standard of care (temozolomide) in patients with recently diagnosed glioblastoma, a type of brain cancer.

All patients will be administered temozolomide, the standard treatment for glioblastoma. Half the patients will be randomly assigned to receive rindopepimut and half the patients will be randomly assigned to receive a control called keyhole limpet hemocyanin.

Patients will be treated in a blinded fashion (neither the patient or the doctor will know which arm of the study the patient is on). Patients will be treated until disease progression or intolerance to therapy and all patients will be followed for survival.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Glioblastoma Astrocytoma Brain Diseases Brain Neoplasms Central Nervous System Diseases Central Nervous System Neoplasms Giant Cell Glioblastoma Glioblastoma With Oligodendroglial Component Glioma Gliosarcoma Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Neoplasms, Neuroepithelial Nervous System Diseases Nervous System Neoplasms Neuroectodermal Tumors Small Cell Glioblastoma

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Prince of Wales Hospital, Randwick, New South Wales, Australia

Loading trial locations.

About this study

The purpose of this research study is to find out whether adding an experimental vaccine called rindopepimut (also known as CDX-110) to the commonly used chemotherapy drug temozolomide can help improve the life expectancy of patients with newly diagnosed, resected EGFRvIII positive glioblastoma.

The duration of participation in this study may be up to 5 years. After you are screened and enrolled in the study, you will be administered temozolomide and either rindopepimut/GM-CSF or KLH until either disease progression or intolerance to the medications. If your tumor progresses while on this study, your doctor may treat you with other therapies that are not part of the study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

-

Among other criteria, patients must meet the following conditions to be eligible for the study:

  • Adult patients, ≥ 18 years old
  • Newly diagnosed glioblastoma
  • Attempted surgical resection followed by conventional chemoradiation
  • Documented EGFRvIII positive tumor status by a Sponsor designated laboratory
  • No evidence of progressive disease from the post-operative period to the post-chemoradiation period
  • Candidate for, and agrees to receive, adjuvant (maintenance) temozolomide therapy
  • Systemic corticosteroid therapy at ≤2 mg of dexamethasone or equivalent per day for at least 3 days prior to randomization
  • WHO-ECOG Performance Status ≤ 2
  • Patients of childbearing/reproductive potential will be instructed to use birth control as defined by your doctor.

Exclusion criteria

-

Among other criteria, patients who meet the following conditions are NOT eligible for the study:

  • Stereotactic biopsy only (without further surgical resection)
  • Presence of diffuse leptomeningeal disease, gliomatosis cerebri, or infratentorial disease.
  • History, presence, or suspicion of metastatic disease
  • Patients who have received any additional treatment for glioblastoma, aside from surgical resection and chemoradiation with temozolomide
  • Active systemic infection requiring treatment
  • History of any malignancy (other than glioblastoma) during the last three years except non-melanoma skin cancer, in situ cervical cancer, treated superficial bladder cancer, cured, early-stage prostate cancer in a patient with PSA level less than ULN,or other carcinoma in situ that has been adequately treated and cured.
  • Planned major surgery
  • Evidence of current drug or alcohol abuse
  • Known allergy or hypersensitivity to keyhole limpet hemocyanin (KLH), GM-CSF (sargramostim; LEUKINE®), polysorbate 80 or yeast derived products, or a history of anaphylactic reactions to shellfish proteins
  • Severe acute or chronic medical or psychiatric condition or laboratory abnormality that could increase the risk associated with participating in a clinical trial
  • Women who are pregnant or lactating

Treatment and study plan

Rindopepimut (CDX-110) with GM-CSF

Drug

Two intradermal injections two weeks apart, followed by monthly injections until tumor progression or intolerance.

Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM CSF.

Other names: CDX-110 with sargramostim (GM-CSF) (Leukine®)

Temozolomide

Drug

150 to 200 mg/m2 for 5 days during each 28-day cycle for a minimum of six cycles or a maximum of 12 cycles, or until intolerance or progression.

Other names: Temodar, Temodal

KLH

Drug

Two intradermal injections two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8mL containing approximately 100mcg of KLH.

Primary outcomes

  1. Overall Survival

    Time frame: During treatment and every three months from end of treatment through end of study or approximately up to 5 years.

    The primary efficacy endpoint of Overall Survival is defined as the number of months from randomization to the date of death (whatever the cause), and will be censored for patients who remain alive at completion of the study for patients with a gross total resection (~n=374). The overall survival of patients will be monitored and compared between the two study arms until the end of the study.

Secondary outcomes

  1. Progression-free survival

    Time frame: Every 12 weeks from Day 1 through progression or initiation of other anti-cancer therapy

    Compare progression-free survival between the two treatment arms

  2. Safety and Tolerability

    Time frame: Until day 28 of follow up

    Safety and tolerability will be measured by comparing the two arms in regards to vital sign measurement, physical and neurological examination, adverse events reporting, ECOG performance status, and EORTC core Quality of Life Questionnaire

Sponsors and collaborators

Lead sponsor

Celldex Therapeutics

Industry

Registry information

Official study title

An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma

Acronym: ACT IV

Important dates

Study start
2011
Primary completion
2016
Study completion
2016
First posted
Nov 29, 2011
Registry last updated
Jan 16, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.